http://ift.tt/eA8V8J
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that it has completed its previously announced acquisition of a portfolio of five consumer healthcare products from Sanofi (Euronext: SAN; NYSE: SNY). The most significant product is Prontalgine®, an analgesic for the treatment of moderate to severe pain, only sold in France. The portfolio also includes Buscopan®, an antispasmodic (sold in the Czech Republic, Estonia, Hungary, Latvia, Poland and Slovakia)
May 08, 2017 at 11:11AM
from
No comments:
Post a Comment